HOLX vs. EW: Which Stock Should Value Investors Buy Now?

Core Insights - Hologic (HOLX) has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision compared to Edwards Lifesciences (EW), which has a Zacks Rank of 3 (Hold) [1] - Value investors may find HOLX to be a better investment option due to its superior performance in both Zacks Rank and Style Scores models [3] Valuation Metrics - HOLX has a forward P/E ratio of 18.26, significantly lower than EW's forward P/E of 31.82, suggesting that HOLX may be undervalued [2] - The PEG ratio for HOLX is 2.48, while EW's PEG ratio is higher at 3.22, indicating that HOLX has a more favorable earnings growth expectation relative to its price [2] - HOLX's P/B ratio stands at 3.59, compared to EW's P/B of 7.39, further supporting the notion that HOLX is undervalued relative to its book value [9] Value Assessment - The Value category of the Style Scores system evaluates companies based on key metrics such as P/E ratio, P/S ratio, earnings yield, and cash flow per share to determine fair value [5] - HOLX has a Value grade of B, while EW has a Value grade of D, highlighting HOLX's stronger position in terms of value metrics [6]